Produktname:5-(Methylsulfonyl)nicotinic acid
IUPAC Name:5-methanesulfonylpyridine-3-carboxylic acid
- CAS：893723-59-6
- Molekulare Formel：C7H7NO4S
- Reinheit：97%
- Katalognummer：CM178877
- Molekulargewicht：201.2
Nur für den Einsatz in Forschung und Entwicklung..
Produkt-Details
- CAS-Nr.:893723-59-6
- Molekulare Formel:C7H7NO4S
- Schmelzpunkt:-
- SMILES-Code:O=C(O)C1=CN=CC(S(=O)(C)=O)=C1
- Dichte:
- Katalognummer:CM178877
- Molekulargewicht:201.2
- Siedepunkt:503.1±50.0°C at 760 mmHg
- Mdl-Nr.:MFCD06254799
- Lagerung:Store at 2-8°C.
Category Infos
- Pyridines
- Pyridine is a six-membered heterocyclic compound containing one nitrogen heteroatom. Pyridine and piperidine are the most frequently occurring heterocyclic building blocks in drug molecules. According to incomplete statistics, there are currently more than 180 drugs containing pyridine or piperidine structure that have been marketed, nearly 1/5 of the drugs approved for marketing in recent years contain these two structures.
- Pyridine | C5H5N | Pyridine Supplier/Distributor/Manufacturer - Chemenu
- Pyridine,Pyridine Wholesale,Pyridine for Sale,Pyridine Supplier,Pyridine Distributor,Pyridine Manufacturer
- Pyridine is a basic heterocyclic organic compound with the chemical formula C5H5N. It is structurally related to benzene, with one methine group (=CH−) replaced by a nitrogen atom. It is a highly flammable, weakly alkaline, water-miscible liquid with a distinctive, unpleasant fish-like smell.
Column Infos
- Nelutroctiv
- The Journal of Medicinal Chemistry recently publishes an article titled, “Discovery of Nelutroctiv (CK-136), a Selective Cardiac Troponin Activator for the Treatment of Cardiovascular Diseases Associated with Reduced Cardiac Contractility”. Heart failure (HF) is a lifelong clinical syndrome and remains a major societal concern. Cardiac myosin activators constitute a new class of inotropes and are found to be a viable therapeutic approach for increasing myocardial contractility.
CK-136 is a small molecule cardiac troponin activator that is discovered under a previous joint research program between Cytokinetics and Amgen. It acts on the sarcomere and is designed to improve myocardial contractility by sensitizing cardiac troponin to calcium, increasing actin-myosin cross bridge formation during each cardiac cycle. CK-136 is developed as a potential treatment for heart failure (HF) with reduced ejection fraction (HFrEF) and other types of heart failure, and currently under phase 1 clinical investigation.
Suche 
+86 21 5895 0110 
